Mr Mrs Miss Ms Dr Other

Miss
Ruby
Mullens

Trainee Patent Attorney

London Office

Life sciences

Telephone. +44(0) 161 247 4900
Email. rmullens@hgf.com
Vcard
Linkedin

Experience

Ruby graduated in 2023 with a first class Master's degree in Biochemistry from the University of Oxford, where she was awarded scholarships and academic prizes in recognition of her performance. She since joined HGF in January 2025 as a Trainee Patent Attorney in the Life Science team.

She has a broad technical background, having studied genetics, molecular & cellular biology, metabolic processes, macromolecular structures, drug design, chemical pharmacology, bacterial warfare, antibiotic resistance, and biochemical methods.

During her Master's, Ruby conducted a research project in Neurobiology at the Szele Lab, University of Oxford. Here she explored the role of tumour-associated lncRNAs in neural migration using a range of in-vitro and in-vivo gene editing techniques. In the same year, she completed a comprehensive review of β2-adrenoreceptor signaling in skeletal muscle, offering insights into its therapeutic potential for glucometabolic regulation in type 2 diabetes.

Ruby's particular interests and expertise lie in human metabolism, cellular signaling, cancer biology, and disease pathogenesis at the molecular and cellular level.

Specialisms

Industries

Services

Qualifications

Trainee

MBIOCHEM

MBiochem in Molecular and Cellular Biochemistry, University of Oxford (First Class Honours)

OTHER

Supplemental Subject in Chemical Pharmacology (Distinction)

Recognition

Nuffield Scholarship in Biochemistry, St Hilda's College, University of Oxford

Porter Prize for Performance, Department of Biochemistry, University of Oxford

Proxime Accessit Gibbs Prize for Performance, Department of Biochemistry, University of Oxford

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article
Event - 11th November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Event details

From Stripes to Supermarkets: The Court of Appeal Reaffirms the Need for Precision in Trade Mark Law

On 23 October 2025, Lord Justice Arnold delivered two landmark Court of Appeal decisions addressing trade mark registrability: Thom Browne Inc & Anor v adidas AG [2025] EWCA Civ 1340 …

Read article

Protecting Digital Health innovation in the AI revolution

As artificial intelligence (AI) continues to transform healthcare, from diagnostic imaging and drug discovery to wearable devices and clinical decision support, questions around how to protect these advancements have become …

Read article

Doubling Up on Added Matter at the UPC

Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us